NCT02016872View on ClinicalTrials.gov

Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 16, 2013

Primary Completion Date

July 8, 2024

Study Completion Date

July 8, 2024

Conditions

Non-Small-Cell-Lung Cancer (NSCLC)

Interventions

DRUG

18F-FMISO

OTHER

PET/CT

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02016872 - Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients | Biotech Hunter | Biotech Hunter